protein
| interacting with DCX to regulate cell adhesion |
|
binding partner of ITCH (transient overexpression of FAM/USP9X resulted in the deubiquitylation of ITCH) |
|
interacting with and deubiquitinating monoubiquitinated SMAD4, opposing the activity of Ectodermin/TIF1G (TRIM33), rather than stability |
|
with TRIM33 act as antagonistic SMAD4 regulator during embryonic development |
|
binding MCL1 and removing the Lys48-linked polyubiquitin chains |
|
interacting with MCL1 (stabilizes MCL1 by reversing its polyubiquitination) |
|
interacts with and deubiquitinates SNCA |
|
involved in MCL1 protein turnover by preventing its degradation through the removal of conjugated ubiquitin |
|
SMURF1 is known to bind the C terminus of USP9X and has established roles in cell migration |
|
PMAIP1 over-expression caused a decrease in the USP9X/MCL1 interaction associated with an increase in the MCL1 polyubiquitinated forms |
|
USP9X was found to be the most active deubiquitinase acting on ubiquitin-PEX5 |
|
novel MTOR and CRTC2 binding partner that negatively regulates MTOR activity and skeletal muscle differentiation |
|
USP9X interacts with SMURF1 and stabilizes SMURF1 through deubiquitination |
|
in B lymphocytes, USP9X is required for the induction of PRKCB activity after BCR-dependent activation |
|
USP9X functions as a positive regulatory switch during T lymphocyte priming through removal of inhibitory monoubiquitination from ZAP70 |
|
USP9X is a novel regulator of the translation initiation process via deubiquitination of EIF4A1, which offers new insight in understanding the pivotal role of USP9X in malignancies and neurodevelopmental disorders |
|
deubiquitinase, USP9X interacts with ZBTB38, deubiquitinates it, and stabilizes it |
|
USP9X is a deubiquitinase of PBX1 |